pcn poster

Posters

Psychiatric Nurse Perceptions of Long-Acting Injectable Therapies for Treating Schizophrenia: Qualitative Results From the Multinational ADVANCE Study

Abstract: Background: Psychiatric nurses play a key role in schizophrenia treatment; their perceptions of long-acting injectable antipsychotics (LAIs) vary. The objectives of the Attitude...

08/20/2024

Putting it All Together in Bipolar Disorder: Novel Treatment Options Focused on the Whole Patient

Bipolar disorder (BD) is a serious mental illness and a notoriously challenging disease for healthcare professionals to accurately diagnose and manage. As a result, high rates of undertre...

08/20/2024

Real-World AXS-05 Patient Characteristics in Major Depressive Disorder

Abstract: Introduction: AXS-05 (dextromethorphan-bupropion), a novel, oral, N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist, gained approval from the US FDA i...

08/20/2024

Real-world Change in Depressive Symptoms Among Patients with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray

Abstract: BACKGROUND: Real-world evidence of clinical benefits of esketamine nasal spray for treatment-resistant depression (TRD) is limited. This study used health insurance claims data ...

08/20/2024

Real-World Claims Analysis to Characterize the Burden of Tardive Dyskinesia in Long-Term Care Settings

Abstract: Tardive dyskinesia (TD) is a persistent and potentially debilitating movement disorder associated with antipsychotic exposure. Older adults have an increased risk for TD and may...

08/20/2024

Real-World Safety Profile of Esketamine Nasal Spray During the First 12 Treatment Sessions: An Analysis at 58 Months After Approval in the United States

Abstract: Purpose: To examine real-world incidence of esketamine nasal spray (ESK) treatment-emergent adverse events (TEAEs) of interest (i.e., actively solicited events of sedation, diss...

08/20/2024

Long-Term Safety and Efficacy of Esketamine Nasal Spray by Dosing Frequency in Adults With Treatment-Resistant Depression: Analysis of the SUSTAIN-3 Study

Abstract: Objective: To describe the long-term safety and efficacy of flexibly dosed esketamine nasal spray (ESK) in patients with treatment-resistant depression (TRD) from SUSTAIN-3 (NCT...

08/20/2024

Probiotics as an Adjuvant for Microbiota-gut-brain Axis Dysfunction in Depression

Abstract: Depression is a debilitating disorder, and it is expected to overtake cardiac illnesses as the top source of disease burden in 7 years. It is a psychiatric disorder that is diag...

08/20/2024

Long-Term Safety and Efficacy of Olanzapine/Samidorphan: Results of a 4-Year Open-Label Study

Abstract: Background: Long-term safety, tolerability, and durability of therapeutic effect are important aspects of antipsychotic treatment. Methods: This phase 3, multicenter, open-lab...

08/20/2024

Lumateperone in the Treatment of Patients With Major Depressive Disorder and Bipolar Disorder With Anxious Distress and Mixed Features

Abstract: Background: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder (BD).

08/20/2024

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products